Elite Pharmaceuticals (ELTP) Q2 2025 earnings summary

Executive summary

• Achieved record quarterly revenue of $18.9 million, up 33% year-over-year, driven by higher sales of Elite label products.

• Operating income for the quarter was $3.5 million, up 81% from the prior year quarter, reflecting improved sales and operational leverage.

• Net loss for the quarter was $11.0 million, compared to net income of $14.9 million in the prior year, primarily due to a $12.8 million non-cash expense from the change in fair value of derivative warrants.

• Cash flow from operations turned positive at $4.6 million for the six months, a $7.5 million improvement from the prior year.

• The company expanded its portfolio with new product launches and ANDA acquisitions, and is in its strongest financial position ever.

Financial highlights

• Quarterly revenue grew to $18.9 million from $14.2 million year-over-year; six-month revenue rose to $37.7 million from $23.1 million.

• Operating income for the quarter was $3.5 million, up from $1.9 million; six-month operating income was $7.3 million, up from $3.5 million.

• Gross profit for the quarter was $8.2 million (43% margin), down from 46% year-over-year due to higher labor costs and manufacturing fees.

• Cash and equivalents at September 30, 2024, were $9.6 million, up from $7.1 million at March 31, 2024.

• Working capital increased to $32.4 million, with a $5.5 million rise since March 31.

Outlook and guidance

• Multiple new product launches expected, including hydrocodone/APAP, oxycodone/APAP, and methadone, with regulatory approvals and commercial partnerships pursued.

• Revenue and profit growth expected to continue, targeting a run rate above $70 million for the year.

• Expansion of packaging, warehouse, and manufacturing capacity positions the company for future growth.